Table 1.
Healthy controls (n = 18) | Alzheimer’s disease (n = 27) | LBD (n = 42) | Between-group differences | |
---|---|---|---|---|
Male: female | 11:7 | 20:7 | 36:6 | χ2 = 4.5, P = 0.11a |
Age | 76.3 (5.5) | 74.9 (7.0) | 74.8 (6.4) | F(2,84) = 0.35, P = 0.70b |
AChEI | - | 25 | 36 | χ2 = 0.76, P = 0.38c |
PD meds | - | 1 | 29 | χ2 = 28.6, P < 0.001c |
Duration | - | 3.9 (2.1)f | 3.2 (2.1)g | U = 399, P = 0.12d |
MMSE | 29.2 (0.9) | 20.7 (4.3) | 23.1 (3.7) | t(67) = 2.51, P = 0.01e |
CAMCOG | 96.7 (3.7) | 67.4 (15.7) | 75.7 (11.1) | t(67) = 2.57, P = 0.01e |
UPDRS III | 1.3 (1.5) | 2.4 (3.0) | 20.4 (8.5) | t(67) = 10.6, P < 0.001e |
CAF total | - | 0.38 (0.98)g | 5.0 (4.3)h | t(64) = 5.31, P < 0.001e |
Mayo total | - | 9.4 (4.7)g | 14.0 (5.7)h | t(64) = 3.41, P = 0.001e |
Mayo cogn | - | 1.9 (1.8)g | 2.8 (1.8)h | t(64) = 2.06, P = 0.043e |
NPI total | - | 6.8 (6.6)g | 14.3 (10.5)i | t(65) = 3.23, P = 0.002e |
NPI hall | - | 0.04 (0.20)g | 1.9 (2.0)i | t(65) = 4.90, P < 0.001e |
Values are mean (SD).
AChEI = number of patients taking acetylcholinesterase inhibitors; CAF total = Clinician Assessment of Fluctuation total score; CAMCOG = Cambridge Cognitive Examination; Duration = duration of cognitive symptoms in years; LBD = Lewy body dementia; Mayo total = Mayo Fluctuations Scale; Mayo cognitive = Mayo Fluctuation cognitive subscale; MMSE = Mini-Mental State Examination; PD meds = number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms; UPDRS III = Unified Parkinson’s Disease Rating Scale III (motor subsection); NPI = Neuropsychiatric Inventory; NPI hall = NPI hallucination subscore.
aChi-square test healthy controls, Alzheimer’s disease, Lewy body dementia.
bOne-way ANOVA healthy controls, Alzheimer’s disease, Lewy body dementia.
cChi-square test Alzheimer’s disease, Lewy body dementia.
dMann Whitney U-test Alzheimer’s disease, Lewy body dementia.
eStudent’s t-test Alzheimer’s disease, Lewy body dementia.
f n = 25, gn = 26, hn = 40, in = 41.